Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13656356 | 0.88 | CYP1A2 (0.33) | CYP1A2MAPK1 | |
| SCHEMBL15183477 | 0.85 | CYP1A2 (0.34) | CYP1A2MAPK1 | |
| SCHEMBL13602680 | 0.83 | CYP1A2 (0.33) | CYP1A2MAPK1 | |
| SCHEMBL16202939 | 0.82 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL17523761 | 0.81 | CYP1A2 (0.32) | CYP1A2MAPK1ALDH1A1 | |
| SCHEMBL17523777 | 0.81 | CYP1A2 (0.32) | CYP1A2MAPK1ALDH1A1 | |
| SCHEMBL20208297 | 0.80 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL20438489 | 0.78 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL13656355 | 0.77 | PIK3CD (0.48) | PIK3CD | |
| SCHEMBL3217467 | 0.76 | TSHR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150258068-A1 | COMBINATION THERAPIES | MEI PHARMA, INC. | 2015-09-17 | — | — | US | disclosed |
| US-8143282-B2 | Heterocyclic compounds | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S'BIO PTE LTD (SG) | 2010-04-22 | — | — | US | disclosed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048300-A1 | Heterocyclic Compounds | HDAC1, HDAC3, HDAC11 | CYP1A2 1807/4885MAPK1 1995/4885CA12 1998/4885 |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | PAICS, HDAC5, HDAC4 | CYP1A2 107/4885MAPK1 4685/4885CA12 636/4885 |
| US-20150258068-A1 | COMBINATION THERAPIES | HDAC1, HDAC8, HDAC5 | CYP1A2 4728/4885MAPK1 4237/4885CA12 3108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.